Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec(TM)) 
recently announced that it has received registration approval from Japan 
Pharmaceuticals and Medical Devices Agency (PMDA) for its 
independently-developed Hyperflex(R) Balloon Catheter (Hyperflex(R)) as the 
company's first product approved for marketing in Japan. Hyperflex(R) obtained 
CE Mark in 2016 and is already available in overseas markets in South America 
and Asia.

Hyperflex(R) is intended to assist in the dilation of aortic stent graft. It 
uses a compliant TPU balloon to expand the deployed stent graft, which enables 
improved adherence to the vascular wall, minimizes type I/III endoleaks, and 
improves stent positioning for better short- and long-term outcomes. When used 
in conjunction with the aortic stent graft system, Hyperflex(R) provides an 
integrated endovascular aneurysm repair(EVAR) solution, making it easier and 
more flexible.

Mr. Qing Zhu, President of Endovastec(TM), stated, "The approval of the 
Hyperflex(R) Balloon Catheter in Japan signals a growing acceptance of our EVAR 
devices in more and more national and regional healthcare systems, paving the 
way for the company's continued marketing in Asia and the globe. Endovastec(TM) 
will continue to innovate to improve solutions for aortic diseases and reach 
more patients worldwide with better products and services."

About Endovastec(TM)

Founded in Shanghai in 2012, Shanghai MicroPort Endovascular MedTech (Group) 
Co., Ltd. ("Endovastec(TM)", Stock code: 688016.SH), a subsidiary of MicroPort 
Scientific Corporation ("MicroPort(R)", Stock code: 00853.HK), is a global 
medical devices company focusing on R&D, manufacturing, and sales of aortic and 
peripheral vascular interventional devices, with main products of thoracic and 
abdominal aortic stent grafts, stent grafts in surgical operation, drug coated 
PTA balloon catheters, and PTA balloon catheters etc. At Endovastec(TM), we are 
breaking barriers and accelerating access to provide trustworthy and universal 
access to state-of-the-art solutions of prolonging and reshaping all lives, and 
to build a people centric enterprise ranking as a global leader of evolving and 
emerging medical technologies through continuous innovation.


SOURCE: Endovastec